SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : LIPO-Liposome
LIPO 0.3090.0%Dec 5 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Marc Bertoglio who wrote (556)11/26/1997 11:19:00 AM
From: Fred Puppet   of 900
 
The normal way that brokerage analyst recommendations are distributed is as follows. First, the internal traders get the information. Second, the most valued large customers get it. The retail customers are third. Last comes the release to the general public.

Public releases of upgrades are almost always preceded by strong buying from the first three categories. Downgrades are preceded by selling.

If UBS saw something impressive in last Friday's news (11/21), then there should have been strong buying this week, prior to a public upgrade. But Monday's close was lower than last Fridays, Tuesday was lower still, and today certainly is not showing much buying. That makes me wonder if a downgrade isn't in the works.

The briefing to analysts on 11/21 may have been useful for people who have never followed the company. However, it didn't really contain any new information. So, if the fundamentals have not changed, but the stock jumps up over 25%, which way are they going to change their recommendations?

Of course, this is pure speculation. I don't know for sure that a downgrade is coming.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext